173 related articles for article (PubMed ID: 33921129)
1. Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents.
Lee J; Kang J; Kwon NY; Sivaraman A; Naik R; Jin SY; Oh AR; Shin JH; Na Y; Lee K; Lee HJ
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33921129
[TBL] [Abstract][Full Text] [Related]
2. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
3. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
4. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan.
Su Y; Hu P; Lee SH; Sinko PJ
J Pharm Pharm Sci; 2007; 10(4):519-36. PubMed ID: 18261372
[TBL] [Abstract][Full Text] [Related]
5. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
6. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
Drug Metab Dispos; 2013 Aug; 41(8):1514-21. PubMed ID: 23686319
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
[TBL] [Abstract][Full Text] [Related]
8. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells.
Jia P; Wu S; Li F; Xu Q; Wu M; Chen G; Liao G; Wang S; Zhou J; Lu Y; Ma D
Int J Gynecol Cancer; 2005; 15(6):1042-8. PubMed ID: 16343180
[TBL] [Abstract][Full Text] [Related]
11. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
Oostendorp RL; Buckle T; Beijnen JH; van Tellingen O; Schellens JH
Invest New Drugs; 2009 Feb; 27(1):31-40. PubMed ID: 18449471
[TBL] [Abstract][Full Text] [Related]
12. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
13. Topotecan is a substrate for multidrug resistance associated protein 4.
Tian Q; Zhang J; Chan SY; Tan TM; Duan W; Huang M; Zhu YZ; Chan E; Yu Q; Nie YQ; Ho PC; Li Q; Ng KY; Yang HY; Wei H; Bian JS; Zhou SF
Curr Drug Metab; 2006 Jan; 7(1):105-18. PubMed ID: 16454695
[TBL] [Abstract][Full Text] [Related]
14. [The mechanism of topotecan resistance in ovarian cancer cell line].
Jia P; Wu SB; Li F; Xu Q; Wu MF; Liao GN; Lu YP; Ma D
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):139-42. PubMed ID: 15196431
[TBL] [Abstract][Full Text] [Related]
15. Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.
Li H; Jin HE; Kim W; Han YH; Kim DD; Chung SJ; Shim CK
Pharm Res; 2008 Nov; 25(11):2601-12. PubMed ID: 18654741
[TBL] [Abstract][Full Text] [Related]
16. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
Yamasaki T; Fujinaga M; Kawamura K; Hatori A; Yui J; Nengaki N; Ogawa M; Yoshida Y; Wakizaka H; Yanamoto K; Fukumura T; Zhang MR
Nucl Med Biol; 2011 Jul; 38(5):707-14. PubMed ID: 21718946
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)
Chong TC; Wong ILK; Cui J; Law MC; Zhu X; Hu X; Kan JWY; Yan CSW; Chan TH; Chow LMC
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362047
[TBL] [Abstract][Full Text] [Related]
19. Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer.
Guo J; Wang Q; Zhang Y; Sun W; Zhang S; Li Y; Wang J; Bao Y
Pharmacol Res; 2019 Sep; 147():104387. PubMed ID: 31408695
[TBL] [Abstract][Full Text] [Related]
20. [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].
Jia P; Wu SB; Xu Q; Wu MF; Gao QL; Liao GN; Lu YP; Ma D
Ai Zheng; 2003 Dec; 22(12):1296-300. PubMed ID: 14693055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]